137 related articles for article (PubMed ID: 19005267)
21. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
Sharma S; Schlusser KE; de la Torre P; Tambussi G; Draenert R; Pinto AN; Metcalf JA; Neaton JD; Laeyendecker O;
AIDS; 2019 Jul; 33(8):1335-1344. PubMed ID: 31157663
[TBL] [Abstract][Full Text] [Related]
22. Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy.
Pantazis N; Papastamopoulos V; Paparizos V; Metallidis S; Adamis G; Antoniadou A; Psichogiou M; Chini M; Sambatakou H; Sipsas NV; Gogos C; Chrysos G; Panagopoulos P; Katsarou O; Gikas A; Touloumi G;
AIDS; 2019 Aug; 33(10):1645-1655. PubMed ID: 31305332
[TBL] [Abstract][Full Text] [Related]
23. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
; Cain LE; Logan R; Robins JM; Sterne JA; Sabin C; Bansi L; Justice A; Goulet J; van Sighem A; de Wolf F; Bucher HC; von Wyl V; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Perez-Hoyos S; Muga R; Lodi S; Lanoy E; Costagliola D; Hernan MA
Ann Intern Med; 2011 Apr; 154(8):509-15. PubMed ID: 21502648
[TBL] [Abstract][Full Text] [Related]
24. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study.
; Judd A; Chappell E; Turkova A; Le Coeur S; Noguera-Julian A; Goetghebuer T; Doerholt K; Galli L; Pajkrt D; Marques L; Collins IJ; Gibb DM; González Tome MI; Navarro M; Warszawski J; Königs C; Spoulou V; Prata F; Chiappini E; Naver L; Giaquinto C; Thorne C; Marczynska M; Okhonskaia L; Posfay-Barbe K; Ounchanum P; Techakunakorn P; Kiseleva G; Malyuta R; Volokha A; Ene L; Goodall R
PLoS Med; 2018 Jan; 15(1):e1002491. PubMed ID: 29381702
[TBL] [Abstract][Full Text] [Related]
25. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy.
Keiser O; MacPhail P; Boulle A; Wood R; Schechter M; Dabis F; Sprinz E; Egger M;
Trop Med Int Health; 2009 Oct; 14(10):1220-5. PubMed ID: 19624478
[TBL] [Abstract][Full Text] [Related]
26. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD).
Egger S; Petoumenos K; Kamarulzaman A; Hoy J; Sungkanuparph S; Chuah J; Falster K; Zhou J; Law MG;
J Acquir Immune Defic Syndr; 2009 Apr; 50(5):513-20. PubMed ID: 19408354
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
[TBL] [Abstract][Full Text] [Related]
28. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
29. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
30. HLA B*5701 status, disease progression, and response to antiretroviral therapy.
UK Collaborative HIV Cohort Study Steering Committee
AIDS; 2013 Oct; 27(16):2587-92. PubMed ID: 23921616
[TBL] [Abstract][Full Text] [Related]
31. Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.
Cohen S; Smit C; van Rossum AM; Fraaij PL; Wolfs TF; Geelen SP; Schölvinck EH; Warris A; Scherpbier HJ; Pajkrt D;
AIDS; 2013 Oct; 27(16):2567-75. PubMed ID: 23842124
[TBL] [Abstract][Full Text] [Related]
32. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts.
Almeida JM; Letang E; Nhampossa T; Ayala E; David C; Menendez C; Gascon J; Alonso P; Naniche D
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):705-11. PubMed ID: 21091388
[TBL] [Abstract][Full Text] [Related]
33. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.
Touloumi G; Pantazis N; Pillay D; Paraskevis D; Chaix ML; Bucher HC; Kücherer C; Zangerle R; Kran AM; Porter K;
Clin Infect Dis; 2013 Mar; 56(6):888-97. PubMed ID: 23223594
[TBL] [Abstract][Full Text] [Related]
34. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
35. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study.
Wolbers M; Bucher HC; Furrer H; Rickenbach M; Cavassini M; Weber R; Schmid P; Bernasconi E; Hirschel B; Battegay M;
HIV Med; 2008 Jul; 9(6):397-405. PubMed ID: 18410354
[TBL] [Abstract][Full Text] [Related]
36. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters.
Madec Y; Boufassa F; Porter K; Meyer L;
AIDS; 2005 Nov; 19(17):2001-7. PubMed ID: 16260907
[TBL] [Abstract][Full Text] [Related]
37. Effect of early versus deferred antiretroviral therapy for HIV on survival.
Kitahata MM; Gange SJ; Abraham AG; Merriman B; Saag MS; Justice AC; Hogg RS; Deeks SG; Eron JJ; Brooks JT; Rourke SB; Gill MJ; Bosch RJ; Martin JN; Klein MB; Jacobson LP; Rodriguez B; Sterling TR; Kirk GD; Napravnik S; Rachlis AR; Calzavara LM; Horberg MA; Silverberg MJ; Gebo KA; Goedert JJ; Benson CA; Collier AC; Van Rompaey SE; Crane HM; McKaig RG; Lau B; Freeman AM; Moore RD;
N Engl J Med; 2009 Apr; 360(18):1815-26. PubMed ID: 19339714
[TBL] [Abstract][Full Text] [Related]
38. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
39. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
Siegfried N; Uthman OA; Rutherford GW
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
[TBL] [Abstract][Full Text] [Related]
40. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.
Lodi S; Meyer L; Kelleher AD; Rosinska M; Ghosn J; Sannes M; Porter K
Arch Intern Med; 2012 Sep; 172(16):1252-5. PubMed ID: 22826124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
